The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
|Articles|May 1, 2000
The American Journal of Managed Care
- May 2000
- Volume 6
- Issue 5
Relationship of Hemoglobin A1C, Age of Diabetes Diagnosis, and Ethnicity to Clinical Outcomes and Medical Costs in a Computer-Simulated Cohort of Persons with Type 2 Diabetes
Advertisement
Articles in this issue
over 26 years ago
Disease Management Program Improves Asthma Outcomesover 26 years ago
The Inpatient Specialist: What is the Difference?over 26 years ago
Teaching Managed Care Principles: We Need to Do BetterAdvertisement
Related to this article
Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content spanning from glaucoma to dry eye.
A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Bumetanide nasal spray is bioequivalent to oral bumetanide in 68 healthy adults; Esperion is targeting heart failure care before a 2027 CMS payment model.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
FDA Approves First Symptomatic Dermographism Treatment
3
Sacral Neuromodulation Still Seen as OAB Gold Standard in Review
4
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
5